PsychedelicNewsBreaks

TuesdayOct 27, 2020 1:58 pm

PsychedelicNewsBreaks – Rritual Mushrooms Inc.’s New Line of Elixirs Provides ‘Daily Dose’ with Powerful Benefits

Rritual, a plant-based consumer wellness brand, is positioning to take advantage of opportunity in the functional food and mushroom market with the fall launch of its innovative suite of premium functional mushroom and adaptogenic elixirs. “The health and wellness benefits of mushrooms and plant-based therapies are backed by decades of scientific research,” Dr. Mike Hart, president of Rritual, who also oversaw the development of the new line of products, stated of the launch (https://ibn.fm/bW2n6). “Rritual’s new line of elixirs embraces that research and provides consumers with an easy way to get a daily dose of the powerful effects.” To view…

Continue Reading

TuesdayOct 20, 2020 1:36 pm

PsychedelicNewsBreaks – Pure Extract Technologies Inc. Looks to Production of Highest-Quality FSO

Pure Extract, a private, plant-based extraction company, was recently awarded a Standard Processing License by Health Canada under the Cannabis Act. Following this significant milestone, Pure Extracts will now proceed with application to Health Canada for a Natural Health Products Site License at its purpose-built extraction facility while adhering to EU Good Manufacturing Practices (“GMP”). This will help to enable the company to extract its full spectrum oil (“FSO”) to the highest-possible quality. “We are thrilled to be commencing production in our new, EU-GMP compliant, purpose-built facility,” stated Pure Extracts founder and COO Doug Benville in a recent article discussing…

Continue Reading

TuesdayOct 20, 2020 1:13 pm

PsychedelicNewsBreaks – Why Rritual Mushrooms Inc. Is ‘One to Watch’

Rritual is a private company and premium brand in the emerging functional mushrooms market. The company is dedicated to helping people meet the demands of modern life with style and ease by enriching their diets through incorporating functional mushrooms, adaptogens and superfoods. Rritual manufactures premium plant-based products, with each featuring mindfully selected ingredients and designed to fit every lifestyle and meet the demands of customers with various needs. A recent article discussing the company reads, “Rritual recently announced the launch of its suite of premium functional mushroom and adaptogenic elixirs. These elixirs were developed by a leading team of scientists,…

Continue Reading

WednesdayOct 14, 2020 3:26 pm

PsychedelicNewsBreaks – Pure Extract Technologies Inc. Eyes Opportunity as Psilocybin Shows Promise for Treating Depression

Pure Extract Technologies, a private, plant-based extraction company, is positioned for opportunity as interest grows in the psychedelic and functional mushrooms sector. Recent groundbreaking research indicates that psilocybin-assisted psychotherapy may be effective in treating depression, a debilitating disorder that plagues an estimated 300 million people across the United States. According to a recent National Centre for Mental Health (“NCMH”) article, “a small number of studies have been conducted trialing psilocybin on patients with treatment-resistant depression.” Test results showed a significant decrease in depression scores after only one week to three months, with the majority of participants experiencing reduced depression severity…

Continue Reading

MondayOct 12, 2020 2:49 pm

PsychedelicNewsBreaks – Cybin Corp. Holds Distinct Strength in Psychedelics Space

Cybin Corp., a Canada-based, life-science company, is focused on the development of mushroom-derived psychedelic pharmaceuticals and nonpsychedelic nutraceutical products. The company is positioning as countries around the world become increasingly accepting of psilocybin’s use in controlled settings and recent clinical studies unveil its potential in treating mental health disorders and other conditions. A recent article discussing the company’s pioneering efforts on this front reads, “Cybin already holds a unique strength in the psychedelics space. The company is responsible for some of the first published research on microdosing; i.e, the action or practice of taking or administering very small amounts of…

Continue Reading

ThursdayOct 08, 2020 1:24 pm

PsychedelicNewsBreaks – Pure Extract Technologies Inc. Positioning as Research Looks to the ‘Magic’ in Mushrooms

Pure Extract Technologies, a private, plant-based extraction company, is positioning for opportunity amid the ramping up of next-generation research regarding potential benefits of functional mushrooms and psilocybin compounds. The company is pursuing a Natural Health Products Site License from Health Canada to buy, sell and produce functional mushroom products in an EU-GMP-compliant environment. This will position Pure Extracts to partner with organizations that plan to develop both functional and psychedelic products. The timing appears optimal as further studies aim to explore the benefits of psychedelics, including potential anti-tumor effects, improved immune function, mental wellness, detoxification and more. A recent article…

Continue Reading

WednesdayOct 07, 2020 11:25 am

PsychedelicNewsBreaks – Rritual Mushrooms Inc. Engages InvestorBrandNetwork

Rritual Mushrooms, a premium brand in the emerging functional mushroom market, has announced that it has selected InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, for its communication needs. Founded in 2019, Rritual Mushrooms is a private company with a declared purpose to help people meet the demands of modern life with style and ease by incorporating functional mushrooms, adaptogens and superfoods into their diets. Rritual Mushrooms engaged IBN to leverage its investor-based distribution network of more than 5,000 key syndication outlets, social media channels, wire services and more to tell the Rritual story. That story includes Rritual’s ability to…

Continue Reading

MondayOct 05, 2020 10:54 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Elects Leading International Expert as Board Chairman

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), today announced the election of Dr. Roger McIntyre as chairman of its board of directors. A foremost international expert in depression and suicide, Dr. McIntyre is a professor of Psychiatry and Pharmacology at the University of Toronto, heads the Mood Disorders Unit at the University Health Network in Toronto and holds appointments among scientific and clinical organizations across the United States and Asia. Dr. McIntyre was appointed to Champignon’s board in July 2020 and assumed the role of CEO in May 2020. He has set a strategic direction for the business, which…

Continue Reading

FridayOct 02, 2020 1:28 pm

PsychedelicNewsBreaks – Cybin Corp. CEO Eyes Opportunity in Psychedelics Space, Organic IP Expansion

Cybin Corp., a Canada-based, life-science company developing mushroom-derived psychedelic pharmaceuticals and nonpsychedelic nutraceutical products, recently announced the appointment of Doug Drysdale as the company’s chief executive officer. Well recognized in the pharmaceutical space, Drysdale brings more than three decades of experience and a recognition of psychedelics as a major breakthrough in treating mental health conditions. Amid the recent strong push for research and commercialization in the psychedelics sector, Drysdale seeks to pursue emerging opportunities and pave the road for the company’s rapid growth. “I am beyond excited to be joining the Cybin team,” Drysdale stated in a recent article of…

Continue Reading

FridaySep 25, 2020 2:07 pm

PsychedelicNewsBreaks – Cybin Corp. Leverages Two-Pronged Approach to Target Psychedelic, Nutraceutical Sectors

Cybin Corp., a Canada-based life-science company, looks to benefit from its growing footprint in two billion-dollar markets: nutraceuticals and psychedelic drugs. Both sectors are projected to see significant growth in the coming years. The global nutraceutical market was valued at $382.51 billion in 2019 and is expected to grow at an 8.3% compound annual growth rate (“CAGR”) over the next seven years. Meanwhile, the psychedelic drugs market is projected to reach $6.85 billion by 2027. Cybin’s business model is structured around two wholly owned divisions focused on targeting both promising spaces. A recent article discussing this reads, “Cybin is committed…

Continue Reading